These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32070681)

  • 21. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.
    Madhi SA; Koen A; Jose L; van Niekerk N; Adrian PV; Cutland C; François N; Ruiz-Guiñazú J; Yarzabal JP; Moreira M; Borys D; Schuerman L
    Medicine (Baltimore); 2017 Jan; 96(2):e5881. PubMed ID: 28079828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.
    Madhi SA; Violari A; Klugman KP; Lin G; McIntyre JA; von Gottberg A; Jean-Philippe P; Cotton MF; Adrian P;
    Vaccine; 2011 Sep; 29(40):6994-7001. PubMed ID: 21787822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.
    Santosham M; Englund JA; McInnes P; Croll J; Thompson CM; Croll L; Glezen WP; Siber GR
    Pediatr Infect Dis J; 2001 Oct; 20(10):931-40. PubMed ID: 11642626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.
    van den Biggelaar AHJ; Richmond PC; Fuery A; Anderson D; Opa C; Saleu G; Lai M; Francis JP; Alpers MP; Pomat WS; Lehmann D
    PLoS One; 2017; 12(10):e0185877. PubMed ID: 29028802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age.
    King JC; Vink PE; Chang I; Kimura A; Parks M; Smilie M; Lichenstein R; Farley JJ
    Vaccine; 1998 Feb; 16(4):361-5. PubMed ID: 9607056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.
    Ohtola JA; Khaskhely NM; Saul-Mcbeth JL; Iyer AS; Leggat DJ; Khuder SA; Westerink MAJ
    Vaccine; 2016 Jan; 34(4):451-457. PubMed ID: 26707220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
    Uffman EA; Li SH; Chen JL; Allen N; Boiditswe S; Fouda GG; Hurst JH; Patel MZ; Steenhoff AP; Cunningham CK; Qin E; Davenport CA; Kelly MS
    Vaccine; 2022 Aug; 40(33):4764-4771. PubMed ID: 35773120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
    King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
    Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Pediatr Infect Dis J; 2002 Nov; 21(11):1004-7. PubMed ID: 12442020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.
    Rose MA; Schubert R; Strnad N; Zielen S
    Clin Diagn Lab Immunol; 2005 Oct; 12(10):1216-22. PubMed ID: 16210486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger KS; Hogerman DA; Madore DV; Chang I; Paradiso PR; Malinoski FJ; Kimura A
    Pediatrics; 1998 Apr; 101(4 Pt 1):604-11. PubMed ID: 9521941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.
    Licciardi PV; Toh ZQ; Clutterbuck EA; Balloch A; Marimla RA; Tikkanen L; Lamb KE; Bright KJ; Rabuatoka U; Tikoduadua L; Boelsen LK; Dunne EM; Satzke C; Cheung YB; Pollard AJ; Russell FM; Mulholland EK
    J Allergy Clin Immunol; 2016 Jun; 137(6):1772-1779.e11. PubMed ID: 26825000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies.
    Wysocki J; Brzostek J; Konior R; Panzer FG; François NA; Ravula SM; Kolhe DA; Song Y; Dieussaert I; Schuerman L; Borys D
    Hum Vaccin Immunother; 2017 Mar; 13(3):661-675. PubMed ID: 27736293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants.
    Zangwill KM; Greenberg DP; Chiu CY; Mendelman P; Wong VK; Chang SJ; Partridge S; Ward JI
    Vaccine; 2003 May; 21(17-18):1894-900. PubMed ID: 12706674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.
    Ohtola JA; Saul-McBeth JL; Iyer AS; Leggat DJ; Khuder SA; Khaskhely NM; Westerink MJ
    J AIDS Clin Res; 2016 Mar; 7(3):. PubMed ID: 27158552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.